<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T11:00:38Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:6616219" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:6616219</identifier>
        <datestamp>2019-07-28</datestamp>
        <setSpec>springeropen</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Mol Imaging Biol</journal-id>
              <journal-id journal-id-type="iso-abbrev">Mol Imaging Biol</journal-id>
              <journal-title-group>
                <journal-title>Molecular Imaging and Biology</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">1536-1632</issn>
              <issn pub-type="epub">1860-2002</issn>
              <publisher>
                <publisher-name>Springer International Publishing</publisher-name>
                <publisher-loc>Cham</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC6616219</article-id>
              <article-id pub-id-type="pmcid">PMC6616219</article-id>
              <article-id pub-id-type="pmc-uid">6616219</article-id>
              <article-id pub-id-type="pmid">30250989</article-id>
              <article-id pub-id-type="publisher-id">1262</article-id>
              <article-id pub-id-type="doi">10.1007/s11307-018-1262-3</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Research Article</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Does Measurement of First-Order and Heterogeneity Parameters Improve Response Assessment of Bone Metastases in Breast Cancer Compared to SUV<sub>max</sub> in [<sup>18</sup>F]fluoride and [<sup>18</sup>F]FDG PET?</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author" corresp="yes">
                  <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-2999-0023</contrib-id>
                  <name>
                    <surname>Azad</surname>
                    <given-names>Gurdip K.</given-names>
                  </name>
                  <address>
                    <phone>+44 207 188 8364</phone>
                    <email>gurdip.azad@kcl.ac.uk</email>
                  </address>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Cousin</surname>
                    <given-names>Francois</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Siddique</surname>
                    <given-names>Musib</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Taylor</surname>
                    <given-names>Benjamin</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff3">3</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Goh</surname>
                    <given-names>Vicky</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Cook</surname>
                    <given-names>Gary J. R.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                  <xref ref-type="aff" rid="Aff4">4</xref>
                </contrib>
                <aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.425213.3</institution-id><institution>Department of Cancer Imaging, School of Biomedical Engineering &amp; Imaging Sciences, King’s College London, Lambeth Wing, </institution><institution>St Thomas’ Hospital, </institution></institution-wrap>Westminster Bridge Road, London, SE1 7EH UK </aff>
                <aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 8607 6858</institution-id><institution-id institution-id-type="GRID">grid.411374.4</institution-id><institution>Department of Radiology, </institution><institution>Centre Hospitalier Universitaire de Liege, </institution></institution-wrap>Cour des Mineurs 5D, 4000 Liege, Belgium </aff>
                <aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.420545.2</institution-id><institution>Department of Clinical Oncology, </institution><institution>Guys and St Thomas’ Hospital NHS Trust, </institution></institution-wrap>London, UK </aff>
                <aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.425213.3</institution-id><institution>King’s College London &amp; Guy’s and St Thomas’ PET Centre, </institution><institution>St Thomas’ Hospital, </institution></institution-wrap>London, SE1 7EH UK </aff>
              </contrib-group>
              <pub-date pub-type="epub">
                <day>24</day>
                <month>9</month>
                <year>2018</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>24</day>
                <month>9</month>
                <year>2018</year>
              </pub-date>
              <pub-date pub-type="ppub">
                <year>2019</year>
              </pub-date>
              <volume>21</volume>
              <issue>4</issue>
              <fpage>781</fpage>
              <lpage>789</lpage>
              <permissions>
                <copyright-statement>© The Author(s) 2018</copyright-statement>
                <license license-type="OpenAccess">
                  <license-p><bold>Open Access</bold> This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</license-p>
                </license>
              </permissions>
              <abstract id="Abs1">
                <sec>
                  <title>Purpose</title>
                  <p id="Par1">To establish whether first-order statistical features from [<sup>18</sup>F]fluoride and 2-deoxy-2-[<sup>18</sup>F] fluoro-<sc>d</sc>-glucose ([<sup>18</sup>F]FDG) positron emission tomography/x-ray computed tomography (PET/CT) demonstrate incremental value in skeletal metastasis response assessment compared with maximum standardised uptake value (SUV<sub>max</sub>).</p>
                </sec>
                <sec>
                  <title>Procedures</title>
                  <p id="Par2">Sixteen patients starting endocrine treatment for <italic>de novo</italic> or progressive breast cancer bone metastases were prospectively recruited to undergo [<sup>18</sup>F]fluoride and [<sup>18</sup>F]FDG PET/CT scans before and 8 weeks after treatment. Percentage changes in SUV parameters, metabolic tumour volume (MTV), total lesion metabolism (TLM), standard deviation (SD), entropy, uniformity and absolute changes in kurtosis and skewness, from the same ≤ 5 index lesions, were measured. Clinical response to 24 weeks, assessed by two experienced oncologists blinded to PET/CT imaging findings, was used as a reference standard and associations were made between parameters and progression free and overall survival.</p>
                </sec>
                <sec>
                  <title>Results</title>
                  <p id="Par3">[<sup>18</sup>F]fluoride PET/CT: In four patients (20 lesions) with progressive disease (PD), TLM and kurtosis predicted PD better than SUV<sub>max</sub> on a patient basis (4, 4 and 3 out of 4, respectively) and TLM, entropy, uniformity and skewness on a lesion basis (18, 16, 16, 18 and 15 out of 20, respectively). Kurtosis was independently associated with PFS (<italic>p</italic> = 0.033) and OS (<italic>p</italic> = 0.008) on Kaplan-Meier analysis. [<sup>18</sup>F]FDG PET: No parameter provided incremental value over SUV<sub>max</sub> in predicting PD or non-PD. TLM was significantly associated with OS (<italic>p</italic> = 0.041) and skewness with PFS (<italic>p</italic> = 0.005). Interlesional heterogeneity of response was seen in 11/16 and 8/16 patients on [<sup>18</sup>F]fluoride and [<sup>18</sup>F]FDG PET/CT, respectively.</p>
                </sec>
                <sec>
                  <title>Conclusion</title>
                  <p id="Par4">With [<sup>18</sup>F]fluoride PET/CT, some first-order features, including those that take into account lesion volume but also some heterogeneity parameters, provide incremental value over SUV<sub>max</sub> in predicting clinical response and survival in breast cancer patients with bone metastases treated with endocrine therapy. With [<sup>18</sup>F]FDG PET/CT, no first-order parameters were more accurate than SUV<sub>max</sub> although TLM and skewness were associated with OS and PFS, respectively. Intra-patient heterogeneity of response occurs commonly between metastases with both tracers and most parameters.</p>
                </sec>
              </abstract>
              <kwd-group xml:lang="en">
                <title>Key words</title>
                <kwd>Breast cancer</kwd>
                <kwd>Bone metastases</kwd>
                <kwd>Heterogeneity</kwd>
                <kwd>[<sup>18</sup>F]fluoride PET/CT</kwd>
                <kwd>[<sup>18</sup>F]FDG PET/CT</kwd>
              </kwd-group>
              <funding-group>
                <award-group>
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100004440</institution-id>
                      <institution>Wellcome Trust</institution>
                    </institution-wrap>
                  </funding-source>
                </award-group>
              </funding-group>
              <funding-group>
                <award-group>
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100009794</institution-id>
                      <institution>Breast Cancer Now</institution>
                    </institution-wrap>
                  </funding-source>
                </award-group>
              </funding-group>
              <funding-group>
                <award-group>
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000289</institution-id>
                      <institution>Cancer Research UK</institution>
                    </institution-wrap>
                  </funding-source>
                </award-group>
              </funding-group>
              <funding-group>
                <award-group>
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000265</institution-id>
                      <institution>Medical Research Council</institution>
                    </institution-wrap>
                  </funding-source>
                </award-group>
              </funding-group>
              <funding-group>
                <award-group>
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000272</institution-id>
                      <institution>National Institute for Health Research</institution>
                    </institution-wrap>
                  </funding-source>
                </award-group>
              </funding-group>
              <funding-group>
                <award-group>
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000398</institution-id>
                      <institution>Royal College of Radiologists</institution>
                    </institution-wrap>
                  </funding-source>
                </award-group>
              </funding-group>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>issue-copyright-statement</meta-name>
                  <meta-value>© World Molecular Imaging Society 2019</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
          </front>
          <body>
            <sec id="Sec1">
              <title>Introduction</title>
              <p id="Par5">Skeletal metastases are common in patients with advanced breast cancer and are associated with significant morbidity [<xref ref-type="bibr" rid="CR1">1</xref>]. With the introduction of new systemic therapies that improve survival time, early detection and response assessment of skeletal metastases has become more important. Varied tumour response to treatment is undoubtedly an important factor in the clinical outcome, accentuating the need to have reliable measures to monitor patients for early disease progression in order to allow timely discontinuation of ineffective treatment.</p>
              <p id="Par6">Conventionally, bone scintigraphy has been used to assess breast cancer bone metastases but has certain limitations when assessing treatment response [<xref ref-type="bibr" rid="CR2">2</xref>]. Molecular and functional imaging can improve diagnosis and treatment response assessment of breast cancer bone metastases [<xref ref-type="bibr" rid="CR3">3</xref>]. Standardised uptake value (SUV) on positron emission tomography/computed tomography (PET/CT) has been used as a standard semi-quantitative method for monitoring treatment response but other non-heterogeneity parameters such as metabolic tumour volume (MTV) and tumour lesion metabolism (TLM) have also been used to measure metabolic activity within the tumour [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>]. Several retrospective studies using 2-deoxy-2-[<sup>18</sup>F] fluoro-<sc>d</sc>-glucose ([<sup>18</sup>F]FDG) PET/CT, mainly focusing on osseous response to treatment, have established that a change in SUV<sub>max</sub> can predict disease response or progression [<xref ref-type="bibr" rid="CR6">6</xref>–<xref ref-type="bibr" rid="CR8">8</xref>] and a feasibility study has also shown that [<sup>18</sup>F]fluoride PET may be useful in evaluating treatment response in breast cancer [<xref ref-type="bibr" rid="CR9">9</xref>]. Despite this, there is limited evidence to support the use of either tracer in routine clinical practice. Measuring volumetric parameters or heterogeneity of tracer activity has also been shown to have incremental predictive or prognostic value in a number of cancers [<xref ref-type="bibr" rid="CR10">10</xref>–<xref ref-type="bibr" rid="CR21">21</xref>]. First-order statistics measure global properties of a tumour from individual voxel values and can be obtained from the histogram of voxel intensities and are most commonly used [<xref ref-type="bibr" rid="CR22">22</xref>], but there are no reports on the use of first-order heterogeneity parameters in evaluating treatment response assessment of breast cancer bone metastases using [<sup>18</sup>F]fluoride or [<sup>18</sup>F]FDG PET.</p>
              <p id="Par7">The hypothesis of this study was that global first-order features derived from skeletal metastases, some of which describe heterogeneity in bone metastases, may be a better predictor of response to treatment in comparison with SUV<sub>max</sub>.</p>
              <p id="Par8">The objective of this study was to extract first-order features on both [<sup>18</sup>F]FDG (tumour-specific radiotracer that targets glucose metabolism) and [<sup>18</sup>F]fluoride (bone-specific tracer that targets osteoblast activity and local blood flow) PET/CT images in breast cancer bone metastases, at baseline and 8 weeks after endocrine treatment, and to compare their ability to predict treatment response determined by a clinical reference standard as well as survival with the most commonly described parameter, SUV<sub>max</sub>.</p>
            </sec>
            <sec id="Sec2">
              <title>Materials and Methods</title>
              <sec id="Sec3">
                <title>Participants</title>
                <p id="Par9">Sixteen female breast cancer patients (mean age 51.6, range 40–79 years) starting endocrine treatment for <italic>de novo</italic> (<italic>n</italic> = 5) or progressive bone metastases (<italic>n</italic> = 11) from an ongoing prospective single-centre exploratory study were included. The endocrine treatments used were letrozole (<italic>n</italic> = 12), tamoxifen (<italic>n</italic> = 2), everolimus/exemestane (<italic>n</italic> = 1) and anastrazole (<italic>n</italic> = 1). Apart from two patients who had small volume lung and liver metastases, all other patients had bone-only disease. [<sup>18</sup>F]fluoride and [<sup>18</sup>F]FDG PET/CT scans were acquired before and 8 weeks after starting treatment. The study was approved by a Research Ethics Committee and the Administration of Radioactive Substances Advisory Committee and all patients signed an informed consent form at the time of recruitment.</p>
              </sec>
              <sec id="Sec4">
                <title>[<sup>18</sup>F]FDG PET/CT and [<sup>18</sup>F]fluoride PET/CT Image Acquisition</title>
                <p id="Par10">After injection of [<sup>18</sup>F]FDG (mean 348 ± 18 MBq), PET/CT scans commenced after an uptake time of 60 min. On a separate day following injection of [<sup>18</sup>F]fluoride (mean 228 ± 15 MBq), scans were performed after an uptake time of 60 min. Imaging comprised a static PET/CT scan using a GE Discovery 710 PET/CT scanner (GE Healthcare, Chicago, USA). Each scan covered the base of the skull to mid-thigh, with an axial field-of-view of 15.7 cm and an 11-slice overlap between bed positions. A low-dose CT scan (140 kV, 10 mA, 0.5 s rotation time and 40 mm collimation) was performed at the start of imaging to provide attenuation correction and an anatomical reference. PET scan duration was set to 3 min per bed position.</p>
                <p id="Par11">PET image reconstruction included standard scanner-based corrections for radiotracer decay, scatter, randoms and dead-time. Emission sinograms were reconstructed with a time-of-flight ordered subset expectation maximisation (OSEM) algorithm (2 iterations, 24 subsets), with a 256 × 256 matrix and a 4-mm full-width at half-maximum (FWHM) Gaussian post-reconstruction smoothing filter on the scanner front end, available from the manufacturer.</p>
              </sec>
              <sec id="Sec5">
                <title>Parameter Analysis</title>
                <p id="Par12">Up to five of the most active (SUV ≥ 10) [<xref ref-type="bibr" rid="CR23">23</xref>] and largest (≥ 1 cm diameter) lesions were first identified for analysis on [<sup>18</sup>F]fluoride scans in each subject. Regions of interest (ROIs) were delineated around the same metastasis on the static [<sup>18</sup>F]fluoride and [<sup>18</sup>F]FDG PET/CT scans by an oncologist and radiologist working in consensus (Figs. <xref rid="Fig1" ref-type="fig">1</xref> and <xref rid="Fig2" ref-type="fig">2</xref>). Image heterogeneity analysis was performed using in-house quantitative analysis software implemented in MATLAB (Mathworks, Natick, MA, USA). First-order statistics derived from regional geometry and the histogram distribution of voxel intensities (standard deviation (SD), entropy, uniformity, kurtosis and skewness) on both [<sup>18</sup>F]FDG and [<sup>18</sup>F]fluoride PET scans were calculated as well as non-heterogeneity parameters such as SUV<sub>max</sub>, SUV<sub>mean</sub>, SUV<sub>peak</sub>, TLM and MTV. All parameters on both PET scans were calculated for the same lesions at baseline and 8 weeks, and changes in the values of these parameters from baseline were used for statistical analyses. The tumour volumes were generally small ((mean volume = 7.1 cm<sup>3</sup> (SD = 8.3) on [<sup>18</sup>F]fluoride PET/CT and (mean volume = 5.7 cm<sup>3</sup> (SD = 5.9) on [<sup>18</sup>F]FDG PET/CT)); therefore, in order to avoid bias from small volumes, second and high-order texture features were not calculated [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>]. We also analysed changes in SUV<sub>max</sub> between lesions in each individual patient to assess the degree of interlesional heterogeneity of response with both tracers. Interlesional heterogeneity was defined when a metastasis showed a change in parameter that was opposite to the clinical reference standard.<fig id="Fig1"><label>Fig. 1.</label><caption><p>Figure demonstrating regions of interest in the left humerus in a patient with clinical progressive disease. <bold>a</bold>, <bold>c</bold> [<sup>18</sup>F]FDG and <bold>b</bold>, <bold>d</bold> [<sup>18</sup>F]fluoride PET transaxial slices <bold>a</bold>, <bold>b</bold> before and <bold>c</bold>, <bold>d</bold> 8 weeks after treatment. [<sup>18</sup>F]FDG SUV<sub>max</sub> 14.6 at baseline and 15.4 at 8 weeks. [<sup>18</sup>F]fluoride SUV<sub>max</sub> 37.7 at baseline, 56.5 at 8 weeks and 82.4 at 12 weeks (not shown).</p></caption><graphic xlink:href="11307_2018_1262_Fig1_HTML" id="MO1"/></fig><fig id="Fig2"><label>Fig. 2.</label><caption><p>Figure demonstrating regions of interest in L4 in a patient with non-progressive disease (partial response). <bold>a</bold>, <bold>c</bold> [<sup>18</sup>F]FDG and <bold>b</bold>, <bold>d</bold> [<sup>18</sup>F]fluoride PET transaxial slices <bold>a</bold>, <bold>b</bold> before and <bold>c</bold>, <bold>d</bold> 8 weeks after treatment. [<sup>18</sup>F]FDG SU<sub>Vmax</sub> 8.4 at baseline and 4.4 at 8 weeks. [<sup>18</sup>F]fluoride SUV<sub>max</sub> 72.1 at baseline and 46.5 at 8 weeks.</p></caption><graphic xlink:href="11307_2018_1262_Fig2_HTML" id="MO2"/></fig></p>
                <p id="Par13">Two experienced oncologists working in consensus, blinded to PET/CT findings, determined clinical response based on standard imaging including bone scans and contrast-enhanced CT, clinical assessment, including pain scores (using brief pain inventory questionnaire), as well as alkaline phosphatase and carcinoma antigen 15-3 serology up to 24 weeks after the start of treatment or until progression, whichever came first and was used as a reference standard (Table <xref rid="Tab1" ref-type="table">1</xref>). The changes in clinical parameters were used in patient assessment and none of the parameters were used in isolation. Any discrepancy was reviewed by a third clinician and only one went to a third reader. Assessment decisions were made on bone-only disease, given no soft tissue disease in the majority of this group, so soft tissue response (Response Evaluation Criteria In Solid Tumours (RECIST)) was not relevant in our studied population. Patients were grouped into progressive disease (PD) and non-progressive disease (non-PD = partial response (PR) and stable disease (SD)). PR and SD patients were assessed together as clinical management is rarely different in these two groups.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Different parameters used in each patient for categorisation into PD or non-PD</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Patient</th><th>Disease status</th><th>ALP (alkaline phosphatase)</th><th>Ca-153</th><th>Pain score</th><th>Clinical assessment</th><th>Bone scan</th><th>CT scan</th></tr></thead><tbody><tr><td>1</td><td>PD</td><td>Increased</td><td>Stable</td><td>Worse</td><td>New bone pain</td><td>Not done</td><td>Increase in number of lesions by 24 weeks</td></tr><tr><td>2</td><td>PD</td><td>Increased</td><td>Increased</td><td>Stable</td><td>Weight loss, vomiting</td><td>Increase in number of lesions by 24 weeks</td><td>Increase in number of lesions by 24 weeks</td></tr><tr><td>3</td><td>PD</td><td>Stable</td><td>Increased</td><td>Worse</td><td>New bone pain</td><td>Increase in number of lesions by 24 weeks</td><td>Increase in number of lesions by 24 weeks</td></tr><tr><td>4</td><td>PD</td><td>Increased</td><td>Stable</td><td>Worse</td><td>Worsening bone pain</td><td>Increase in number of lesions by 24 weeks</td><td>Not done</td></tr><tr><td>5</td><td>Non-PD</td><td>Increased</td><td>Increased</td><td>Better</td><td>Better</td><td>No change</td><td>No change</td></tr><tr><td>6</td><td>Non-PD</td><td>Stable</td><td>Decreased</td><td>Better</td><td>Stable symptoms</td><td>Not done</td><td>No change</td></tr><tr><td>7</td><td>Non-PD</td><td>Stable</td><td>Stable</td><td>Better</td><td>Asymptomatic</td><td>No change</td><td>No change</td></tr><tr><td>8</td><td>Non-PD</td><td>Stable</td><td>Stable</td><td>Better</td><td>Better</td><td>No change</td><td>Disappearance of some lesions</td></tr><tr><td>9</td><td>Non-PD</td><td>Better</td><td>Better</td><td>Better</td><td>Stable symptoms</td><td>Not done</td><td>Disappearance of dome lesions</td></tr><tr><td>10</td><td>Non-PD</td><td>Better</td><td>Stable</td><td>Better</td><td>Stable symptoms</td><td>Not done</td><td>No change</td></tr><tr><td>11</td><td>Non-PD</td><td>Stable</td><td>Stable</td><td>Better</td><td>Asymptomatic</td><td>No change</td><td>No change</td></tr><tr><td>12</td><td>Non-PD</td><td>Stable</td><td>Stable</td><td>Better</td><td>Stable symptoms</td><td>No change</td><td/></tr><tr><td>13</td><td>Non-PD</td><td>Stable</td><td>Better</td><td>Stable</td><td>Asymptomatic</td><td>No change</td><td>Disappearance of some lesions</td></tr><tr><td>14</td><td>Non-PD</td><td>Better</td><td>Better</td><td>Better</td><td>Stable symptoms</td><td>No change</td><td>Disappearance of some lesions</td></tr><tr><td>15</td><td>Non-PD</td><td>Stable</td><td>Better</td><td>Better</td><td>Stable symptoms</td><td>Disappearance of some lesions</td><td>Disappearance of some lesions</td></tr><tr><td>16</td><td>Non-PD</td><td>Better</td><td>Stable</td><td>Better</td><td>Stable symptoms</td><td>No change</td><td>No change</td></tr></tbody></table></table-wrap></p>
              </sec>
              <sec id="Sec6">
                <title>Statistical Analysis</title>
                <p id="Par14">Statistical analysis was performed using SPSS for windows version 24 (IBM SPSS Statistics 24). After testing for normality, parametric or nonparametric tests were applied to each set of data. Data that were normally distributed were expressed as a mean and standard deviation and evaluated using the paired <italic>t</italic> test. Data that were not normally distributed were expressed as median and range and evaluated using Wilcoxon signed rank test or Mann-Whitney <italic>U</italic> test. For all statistical tests, a <italic>P</italic> value of ≤ 0.05 was considered statistically significant.</p>
                <p id="Par15">On both [<sup>18</sup>F]fluoride and [<sup>18</sup>F]FDG PET/CT scans, optimum threshold values were established with receiver operating characteristic analysis, maximising the sum of sensitivity and specificity by measuring associated areas under the ROC curves as there are no established criteria for these tracers with endocrine treatment, although ± 25 % has been suggested for [<sup>18</sup>F]FDG post-chemotherapy [<xref ref-type="bibr" rid="CR26">26</xref>] (Tables <xref rid="Tab2" ref-type="table">2</xref> and <xref rid="Tab3" ref-type="table">3</xref>). On this basis, we also used a 25 % cut-off for the SUV parameters on [<sup>18</sup>F]FDG (adapted from the EORTC criteria) and [<sup>18</sup>F]fluoride PET/CT scans, acknowledging that these criteria were described for [<sup>18</sup>F]FDG PET/CT. The values of percentage (%) changes in SUV<sub>max</sub>, SUV<sub>mean</sub>, SUV<sub>peak</sub>, TLG, MTV, entropy, uniformity and absolute changes in skewness and kurtosis, on [<sup>18</sup>F]fluoride and [<sup>18</sup>F]FDG PET/CT scans after 8 weeks of treatment, were calculated for all patients.<table-wrap id="Tab2"><label>Table 2</label><caption><p>Changes in parameter values for PD and non-PD after 8 weeks of treatment on [<sup>18</sup>F]fluoride PET/CT with associated optimum and 25 % cut-off values and AUC</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="3"/><th colspan="7">PD (20 lesions/4 patients)</th><th colspan="5">Non-PD (52 lesions, 12 patients)</th><th rowspan="3"><italic>P</italic> value for PD <italic>vs</italic> non-PD</th></tr><tr><th rowspan="2">Median change (%)</th><th colspan="2">Optimal cut-off (ROC curve analysis)</th><th colspan="2">Number of lesions identified (↑ or ↓)</th><th colspan="2">Number of patients correctly identified (↑ or ↓)</th><th rowspan="2">Median change (%)</th><th colspan="2">Number of lesions identified (↑ or ↓)</th><th colspan="2">Number of patients identified (↑ or ↓)</th></tr><tr><th>Value</th><th>AUC</th><th>Opt cut-off</th><th>25 % cut-off</th><th>Opt cut-off</th><th>25 % cut-off</th><th>Opt cut-off</th><th>25 % cut-off</th><th>Opt cut-off</th><th>25 % cut-off</th></tr></thead><tbody><tr><td>SUVmax (%)</td><td>− 3.0</td><td>− 15.1</td><td>0.67</td><td>15 ↑</td><td>7 ↑</td><td>3 ↑</td><td>2 ↑</td><td>− 20.1</td><td>29 ↓</td><td>47 ↓</td><td>5 ↓</td><td>9 ↓</td><td>0.021</td></tr><tr><td>SUV<sub>mean</sub> (%)</td><td>15.1</td><td>− 2.6</td><td>0.75</td><td>14 ↑</td><td>6 ↑</td><td>3 ↑</td><td>2 ↑</td><td>− 16.0</td><td>38 ↓</td><td>46 ↓</td><td>8 ↓</td><td>9 ↓</td><td>0.001</td></tr><tr><td>SUV<sub>peak</sub> (%)</td><td>3.0</td><td>− 3.9</td><td>0.72</td><td>13↑</td><td>8 ↑</td><td>3 ↑</td><td>2 ↑</td><td>− 17.6</td><td>31 ↓</td><td>46 ↓</td><td>7 ↓</td><td>9 ↓</td><td>0.003</td></tr><tr><td>MTV (%)</td><td>− 2.5</td><td>19.0</td><td>0.51</td><td>14 ↓</td><td/><td>0</td><td/><td>1.1</td><td>44 ↓</td><td/><td>10 ↓</td><td/><td>0.806</td></tr><tr><td>TLM (%)</td><td>9.2</td><td>− 19.0</td><td>0.67</td><td>18 ↑</td><td/><td>4 ↑</td><td/><td>− 11.2</td><td>26 ↑</td><td/><td>8 ↑</td><td/><td>0.023</td></tr><tr><td>SD (%)</td><td>4.9</td><td>9.2</td><td>0.67</td><td>10 ↑</td><td/><td>2 ↑</td><td/><td>− 25.4</td><td>43↓</td><td/><td>8 ↓</td><td/><td>0.022</td></tr><tr><td>Ent (%)</td><td>1.3</td><td>0.6</td><td>0.67</td><td>16 ↑</td><td/><td>3 ↑</td><td/><td>− 0.5</td><td>37 ↓</td><td/><td>5 ↓</td><td/><td>0.020</td></tr><tr><td>Unif (%)</td><td>− 6.6</td><td>1.8</td><td>0.69</td><td>16 ↓</td><td/><td>3 ↓</td><td/><td>2.9</td><td>31 ↑</td><td/><td>7 ↑</td><td/><td>0.012</td></tr><tr><td>Kurt (abs)</td><td>− 0.1</td><td>− 0.005</td><td>0.66</td><td>14 ↓</td><td/><td>4 ↓</td><td/><td>0.04</td><td>31 ↑</td><td/><td>8 ↑</td><td/><td>0.034</td></tr><tr><td>Skew (abs)</td><td>− 0.05</td><td>0.1</td><td>0.5</td><td>18 ↓</td><td/><td>3 ↓</td><td/><td>0.01</td><td>37 ↓</td><td/><td>11 ↓</td><td/><td>0.277</td></tr></tbody></table><table-wrap-foot><p><italic>MTV</italic> metabolic tumour volume, <italic>TLM</italic> tumour lesion metabolism, <italic>SD</italic> standard deviation, <italic>Ent</italic> entropy, <italic>Unif</italic> uniformity, <italic>Kurt</italic> kurtosis, <italic>Skew</italic> skewness, <italic>abs</italic> absolute change, <italic>%</italic> percentage change, ↑ ≥ the cut-off value, ↓ &lt; the cut-off value</p></table-wrap-foot></table-wrap><table-wrap id="Tab3"><label>Table 3</label><caption><p>Changes in parameter values for PD and non-PD after 8 weeks of treatment on [<sup>18</sup>F]FDG PET/CT with associated optimum and 25 % cut-off values and AUC</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="3"/><th colspan="7">PD (20 lesions/4 patients)</th><th colspan="5">Non-PD (52 lesions/12 patients)</th><th rowspan="3"><italic>P</italic> value for PD <italic>vs</italic> non-PD</th></tr><tr><th rowspan="2">Median change</th><th colspan="2">Optimal cut-off (ROC curve analysis)</th><th colspan="2">Number of lesions identified (↑ or ↓)</th><th colspan="2">Number of patients identified (↑ or ↓)</th><th>Median change</th><th colspan="2">Number of lesions identified (↑ or ↓)</th><th colspan="2">Number of patients identified (↑ or ↓)</th></tr><tr><th>Value</th><th>AUC</th><th>Opt cut-off</th><th>25 % cut-off</th><th>Opt cut-off</th><th>25 % cut-off</th><th/><th>Opt cut-off</th><th>25 % cut-off</th><th>Opt cut-off</th><th>25 % cut-off</th></tr></thead><tbody><tr><td>SUV<sub>max</sub> (%)</td><td>− 2.2</td><td>− 20.6</td><td>0.76</td><td>18 ↑</td><td>2 ↑</td><td>4 ↑</td><td>0 ↑</td><td>− 27.2</td><td>33 ↓</td><td>52 ↓</td><td>7 ↓</td><td>12 ↓</td><td>0.001</td></tr><tr><td>SUV<sub>mean</sub> (%)</td><td>0.4</td><td>− 21.7</td><td>0.77</td><td>18 ↑</td><td>1 ↑</td><td>4 ↑</td><td>0 ↑</td><td>− 24.2</td><td>28 ↓</td><td>52 ↓</td><td>4 ↓</td><td>12 ↓</td><td>0.001</td></tr><tr><td>SUV<sub>peak</sub> (%)</td><td>0.6</td><td>− 15.0</td><td>0.76</td><td>17 ↑</td><td>2 ↑</td><td>3 ↑</td><td>0 ↑</td><td>− 24.7</td><td>33 ↓</td><td>52 ↓</td><td>6 ↓</td><td>12 ↓</td><td>0.001</td></tr><tr><td>MTV (%)</td><td>10.7</td><td>− 14.1</td><td>0.70</td><td>17 ↑</td><td/><td>4 ↑</td><td/><td>− 19.7</td><td>30 ↓</td><td/><td>6 ↓</td><td/><td>0.006</td></tr><tr><td>TLM (%)</td><td>4.2</td><td>− 24.1</td><td>0.76</td><td>18 ↑</td><td/><td>4 ↑</td><td/><td>− 40.2</td><td>33 ↓</td><td/><td>6 ↓</td><td/><td>0.001</td></tr><tr><td>SD (%)</td><td>4.1</td><td>− 23.4</td><td>0.72</td><td>16 ↑</td><td/><td>4 ↑</td><td/><td>− 33.5</td><td>33 ↓</td><td/><td>7 ↓</td><td/><td>0.004</td></tr><tr><td>Ent (%)</td><td>− 0.7</td><td>− 2.2</td><td>0.55</td><td>15 ↑</td><td/><td>4 ↑</td><td/><td>− 1.1</td><td>33 ↑</td><td/><td>7 ↑</td><td/><td>0.458</td></tr><tr><td>Unif (%)</td><td>2.8</td><td>5.8</td><td>0.59</td><td>15 ↓</td><td/><td>3 ↓</td><td/><td>4.4</td><td>27 ↓</td><td/><td>6 ↓</td><td/><td>0.235</td></tr><tr><td>Kurt (abs)</td><td>0.1</td><td>0.2</td><td>0.51</td><td>16 ↓</td><td/><td>4 ↓</td><td/><td>0.09</td><td>29 ↓</td><td/><td>7 ↓</td><td/><td>0.826</td></tr><tr><td>Skew (abs)</td><td>0.05</td><td>− 0.13</td><td>0.55</td><td>14 ↑</td><td>0</td><td>4 ↑</td><td>0</td><td>− 0.03</td><td>29 ↑</td><td/><td>6 ↑</td><td/><td>0.517</td></tr></tbody></table><table-wrap-foot><p><italic>MTV</italic> metabolic tumour volume, <italic>TLM</italic> tumour lesion metabolism, <italic>SD</italic> standard deviation, <italic>Ent</italic> entropy, <italic>Unif</italic> uniformity, <italic>Kurt</italic> kurtosis, <italic>Skew</italic> skewness, <italic>abs</italic> absolute change, <italic>%</italic> percentage change, ↑ ≥ the cut-off value, ↓ &lt; the cut-off value</p></table-wrap-foot></table-wrap></p>
                <p id="Par16">Kaplan-Meier analysis was performed using the median value for each parameter to dichotomise the results with differences in the curves tested with the log-rank test. Progression free survival (PFS) was defined as the time between the date of the start of endocrine treatment and the date of disease progression and overall survival (OS) was calculated from the start of endocrine treatment to the date of death or until censoring on the date of the last follow-up.</p>
              </sec>
            </sec>
            <sec id="Sec7">
              <title>Results</title>
              <p id="Par17">There was a total of 16 patients (72 lesions). By the clinical reference standard, 4 patients (20 lesions) had PD at or before 24 weeks and 12 patients (52 lesions) non-PD at 24 weeks. Patients were followed up from between 12 and 49 (median 31.5) months. Four patients died during the follow-up period and all 16 patients progressed at between 2 and 32 (median 11.3) months.</p>
              <p id="Par18">Using the cut-offs that maximised sensitivity and specificity from ROC analysis (Tables <xref rid="Tab2" ref-type="table">2</xref> and <xref rid="Tab3" ref-type="table">3</xref>), on [<sup>18</sup>F]fluoride PET/CT, in all 16 patients, MTV, TLM, kurtosis and skewness performed better than SUV<sub>max</sub> on a patient basis (10, 12, 12, 11 and 8 out of 16, respectively) and SD, entropy, uniformity, kurtosis and skewness on a lesion basis (53, 53, 47, 45, 55 and 44 out of 72, respectively). In the four patients with PD, TLM and kurtosis predicted PD better than SUV<sub>max</sub> on a patient basis (4, 4 and 3 out of 4, respectively) and TLM, entropy, uniformity and skewness on a lesion basis (18, 16, 16, 18 and 15 out of 20, respectively) (Table <xref rid="Tab2" ref-type="table">2</xref>). In the 12 patients with non-PD, [<sup>18</sup>F]fluoride MTV, TLM, SD, uniformity, kurtosis and skewness predicted non-PD better than SUV<sub>max</sub> on a patient basis (10, 8, 8, 7, 8, 11 and 5 out of 12, respectively) and MTV, SD, entropy, uniformity and skewness on a lesion basis (44, 43, 37, 31, 37 and 30 out of 52, respectively (Table <xref rid="Tab2" ref-type="table">2</xref>). On [<sup>18</sup>F]FDG PET/CT, no parameter provided incremental value over SUV<sub>max</sub> overall or in predicting PD or non-PD (Table <xref rid="Tab3" ref-type="table">3</xref>).</p>
              <p id="Par19">In PD and non-PD, on both [<sup>18</sup>F]fluoride PET/CT and [<sup>18</sup>F]FDG PET/CT scans, median % change in first-order features was not statistically significantly different from the median % change in the SUV parameters. On a per lesion basis, on [<sup>18</sup>F]fluoride PET/CT, median % changes in SUV<sub>max</sub>, SUV<sub>mean</sub>, SUV<sub>peak</sub>, TLM, SD and entropy were significantly higher in PD than non-PD (− 3 <italic>vs</italic> − 20.1 % (<italic>p</italic> = 0.021), 15.1 <italic>vs</italic> − 16 % (<italic>p</italic> = 0.001), 3 <italic>vs</italic> − 17.6 % (<italic>p</italic> = 0.003), 9.2 <italic>vs</italic> − 11.2 % (<italic>p</italic> = 0.023), 4.9 <italic>vs</italic> − 25.4 % (<italic>p</italic> = 0.022), 1.3 <italic>vs</italic> − 0.5 % (<italic>p</italic> = 0.020), respectively) and median % changes in uniformity and kurtosis were significantly lower in PD than non-PD (− 6.6 <italic>vs</italic> 2.9 % (<italic>p</italic> = 0.012), − 0.1 <italic>vs</italic> 0.04 % (<italic>p</italic> = 0.034), respectively) (Table <xref rid="Tab2" ref-type="table">2</xref>). On [<sup>18</sup>F]FDG PET/CT, the median % changes in SUV<sub>max</sub>, SUV<sub>mean,</sub> SUV<sub>peak,</sub> MTV, TLM and SD were significantly higher in patients with PD than non-PD (− 2.2 <italic>vs</italic> − 27.2 % (<italic>p</italic> = 0.001), 0.4 <italic>vs</italic> − 24.2 % (<italic>p</italic> = 0.001), 0.6 <italic>vs</italic> − 24.7 % (<italic>p</italic> = 0.001), 10.7 <italic>vs</italic> − 19.7 % (<italic>p</italic> = 0.006), 4.2 <italic>vs</italic> − 40.2 % (<italic>p</italic> = 0.001), 4.1 <italic>vs</italic> − 33.5 % (<italic>p</italic> = 0.004), respectively) (Table <xref rid="Tab3" ref-type="table">3</xref>). Other changes were not statistically significant.</p>
              <p id="Par20">Interlesional heterogeneity of response was seen in 11/16 and 8/16 patients on [<sup>18</sup>F]fluoride and [<sup>18</sup>F]FDG PET/CT, respectively. For [<sup>18</sup>F]fluoride, there was a statistically significant difference between the 15 lesions that showed an increase in SUV<sub>max</sub>, in patients with PD and the 22 lesions that showed an increase in SUV<sub>max</sub> in patients with non-PD for entropy (<italic>p</italic> = 0.028), uniformity (<italic>p</italic> = 0.008) and kurtosis (0.033). No non-PD patient showed new lesions at 8 weeks with either [<sup>18</sup>F]FDG or [<sup>18</sup>F]fluoride PET/CT.</p>
              <p id="Par21">Kaplan-Meier analysis showed that on [<sup>18</sup>F]fluoride PET/CT, at 8 weeks, change in kurtosis had a statistically significant association with PFS (<italic>p</italic> = 0.033) and OS (<italic>p</italic> = 0.008) (Fig. <xref rid="Fig3" ref-type="fig">3</xref>a, b). On [<sup>18</sup>F]FDG PET/CT, change in TLM was significantly associated with OS (<italic>p</italic> = 0.041) and skewness with PFS (<italic>p</italic> = 0.005).<fig id="Fig3"><label>Fig. 3.</label><caption><p>Kaplan-Meier graphs showing worse <bold>a</bold> OS and <bold>b</bold> PFS in patients with negative changes in kurtosis less than the median (<italic>p</italic> = 0.008 and 0.033, respectively) for [<sup>18</sup>F]fluoride PET/CT scans.</p></caption><graphic xlink:href="11307_2018_1262_Fig3_HTML" id="MO3"/></fig></p>
            </sec>
            <sec id="Sec8">
              <title>Discussion</title>
              <p id="Par22">Breast cancer is commonly associated with skeletal metastases and early evaluation of response or progression to treatment is vital to the optimisation of patients’ clinical management. To our knowledge, this is the first report that has evaluated several first-order statistical features, including some heterogeneity parameters, for early treatment response assessment of breast cancer bone metastases compared to standard SUV measures using [<sup>18</sup>F]fluoride and [<sup>18</sup>F]FDG PET/CT.</p>
              <p id="Par23">For [<sup>18</sup>F]fluoride PET/CT, several first-order global parameters showed superiority over SUV<sub>max</sub>, either on a patient-based or lesion-based analysis in predicting PD, including volume-based parameters (MTV, TLM) and heterogeneity parameters (entropy, uniformity, kurtosis and skewness). Additionally, kurtosis was associated with both PFS and OS. Whilst recognition of PD is of most clinical importance, as these patients will need an early transition to second-line therapy, the majority of first-order parameters were also better than SUV<sub>max</sub> at predicting non-PD. The observed changes in patients with PD were as expected, <italic>i.e.,</italic> an increase in activity, volume and/or heterogeneity. In particular, a decrease in kurtosis was also associated with PFS and OS. This relates to an increase in spread (less peakedness) of the voxel intensity histogram (Fig. <xref rid="Fig4" ref-type="fig">4</xref>a, b) or greater “heterogeneity” in voxel values within lesions.<fig id="Fig4"><label>Fig. 4.</label><caption><p>Voxel intensity histograms at <bold>a</bold> baseline (BL) and <bold>b</bold> 8 weeks (8W) with kernel fits of a metastasis in a patient with PD on [<sup>18</sup>F]fluoride PET/CT. As well as an increase in intensity of voxels (SUV<sub>max</sub> rose from 32.7 to 38.0 and SUV<sub>mean</sub> from 12.8–15.3), the histogram becomes less peaked (kurtosis decreased from 5.6 to 3.1).</p></caption><graphic xlink:href="11307_2018_1262_Fig4_HTML" id="MO4"/></fig></p>
              <p id="Par24">Whilst changes in SUV and volume parameters, as well as kinetic analysis, have been reported for monitoring therapy with [<sup>18</sup>F]fluoride PET in bone metastases [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR27">27</xref>–<xref ref-type="bibr" rid="CR29">29</xref>], to our knowledge, there are no data describing superiority of heterogeneity parameters in this situation. However, first-order heterogeneity parameters have shown predictive and prognostic ability in other cancers with [<sup>18</sup>F]FDG PET/CT and increased heterogeneity is usually associated with more aggressive tumours and poor treatment response [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR30">30</xref>].</p>
              <p id="Par25">For [<sup>18</sup>F]FDG PET/CT, no parameter performed better than SUV<sub>max</sub> in predicting response, although an increase in TLM and skewness (shift of histogram to the right with more high intensity voxels) was associated with poor OS and PFS, respectively, whereas SUV<sub>max</sub> was not prognostic. In accordance with our findings, changes in SUV<sub>max</sub> have previously been shown to be valuable in assessing treatment response in breast cancer skeletal metastases [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>].</p>
              <p id="Par26">Heterogeneity of response between metastases is a recognised phenomenon [<xref ref-type="bibr" rid="CR31">31</xref>] and occurred in 11/16 of our patients with [<sup>18</sup>F]fluoride and 8/16 with [<sup>18</sup>F]FDG. The more frequent occurrence with [<sup>18</sup>F]fluoride may be partly explained by the flare phenomenon whereby a temporary increase in osteoblastic activity can occur in healing metastases in non-PD patients [<xref ref-type="bibr" rid="CR32">32</xref>–<xref ref-type="bibr" rid="CR34">34</xref>]. Despite this and the fact that uptake of the two tracers is dependent on differing underlying biological processes (tumour cell glucose metabolism with [<sup>18</sup>F]FDG and osteoblastic mineralisation of bone with [<sup>18</sup>F]fluoride), both tracers offered predictive and prognostic information at a level that would be of clinical utility on a per patient basis. We also observed that entropy, uniformity and kurtosis were significantly different in the 15/20 lesions with a concordant increase in SUV<sub>max</sub> in PD patients compared to a discordant increase in the 22/52 lesions in patients with non-PD, the latter that could be attributed to the flare phenomenon. This would require further prospective validation but the potential to differentiate an increase in uptake due to true progression from the flare phenomenon at 8 weeks would be of great clinical utility when using [<sup>18</sup>F]fluoride PET to measure early response, overcoming one of the limitations of bone-specific imaging.</p>
              <p id="Par27">Limitations of this study include a relatively small number of patients, although we were able to include a large number of individual metastases in the analysis (<italic>n</italic> = 72). In addition, there was a smaller number of patients with PD (<italic>n</italic> = 4) compared to non-PD which may have introduced an element of statistical bias. Whilst all patients had similar treatment, <italic>i.e.,</italic> endocrine therapy, treatment regimens were not exactly the same and there was probably heterogeneity in response. Nevertheless, the main objective of this exploratory study was to measure response rather than treatment-specific effects. Though our study was prospective, these findings deserve further evaluation in larger cohorts as well as in the assessment of different types of therapy and bone metastases from other cancers. Whilst there is no gold standard for determining treatment response in bone metastases, our clinical reference standard was made as robust and clinically relevant as possible by including clinical findings, conventional imaging, biochemistry and tumour markers up to 24 weeks assessed by two oncologists in consensus and we were also able to include a survival analysis as an objective assessment of the measured parameters. Whilst criteria for response assessment have previously been reported for [<sup>18</sup>F]FDG SUV<sub>max</sub> or SUV<sub>peak</sub> [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR35">35</xref>], these criteria have not been applied to other first-order parameters and so we used optimal cut-offs in this exploratory study in addition to 25 % cut-offs for [<sup>18</sup>F]FDG and [<sup>18</sup>F]fluoride conventional SUV parameters. We acknowledge that repeatability of first-order texture features is variable and that the optimal cut-offs for some parameters that have been reported as showing lower repeatability, such as uniformity and skewness [<xref ref-type="bibr" rid="CR36">36</xref>], may be within the limits of repeatability measurements. Several novel parameters still performed better, even when an optimal SUV<sub>max</sub> cut-off was used for comparison.</p>
            </sec>
            <sec id="Sec9">
              <title>Conclusions</title>
              <p id="Par28">Our exploratory data demonstrate that certain first-order statistical features from [<sup>18</sup>F]fluoride and [<sup>18</sup>F]FDG PET, related to volume and heterogeneity, may provide incremental value over SUV<sub>max</sub> in the prediction of treatment response and survival in breast cancer bone metastases treated with endocrine therapy, a finding that deserves confirmation in further prospective evaluation in future studies. In addition, with [<sup>18</sup>F]fluoride some heterogeneity parameters can potentially differentiate an increase in SUV<sub>max</sub> due to flare from that due to progression of disease. These findings may be of potential clinical utility as the prediction of early PD helps oncologists decide whether an earlier switch to more effective therapies is required, whereas non-PD patients would generally continue the same treatment if there were no significant toxicities. We also observed that intra-patient heterogeneity of response occurs commonly between metastases with both tracers and most parameters.</p>
            </sec>
          </body>
          <back>
            <notes notes-type="funding-information">
              <title>Funding Information</title>
              <p>The authors acknowledge financial support from the King’s College London/University College London Comprehensive Cancer Imaging Centres funded by Cancer Research UK and Engineering and Physical Sciences Research Council in association with the Medical Research Council and the Department of Health (C1519/A16463), Breast Cancer Now (2012NovPR013), the Wellcome Trust EPSRC Centre for Medical Engineering at King’s College London (WT203148/Z/16/Z), the Royal College of Radiologists, Alliance Medical Ltd. and the support of the National Institute of Health Research Clinical Research Network (NIHR CRN).</p>
            </notes>
            <notes>
              <title>Compliance with Ethical Standards</title>
              <notes notes-type="COI-statement">
                <title>Conflict of Interest</title>
                <p id="Par29">The authors declare that they have no conflict of interest.</p>
              </notes>
            </notes>
            <ref-list id="Bib1">
              <title>References</title>
              <ref id="CR1">
                <label>1.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Domchek</surname>
                      <given-names>SM</given-names>
                    </name>
                    <name>
                      <surname>Younger</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Finkelstein</surname>
                      <given-names>DM</given-names>
                    </name>
                    <name>
                      <surname>Seiden</surname>
                      <given-names>MV</given-names>
                    </name>
                  </person-group>
                  <article-title>Predictors of skeletal complications in patients with metastatic breast carcinoma</article-title>
                  <source>Cancer</source>
                  <year>2000</year>
                  <volume>89</volume>
                  <fpage>363</fpage>
                  <lpage>368</lpage>
                  <pub-id pub-id-type="doi">10.1002/1097-0142(20000715)89:2&lt;363::AID-CNCR22&gt;3.0.CO;2-3</pub-id>
                  <pub-id pub-id-type="pmid">10918167</pub-id>
                </element-citation>
              </ref>
              <ref id="CR2">
                <label>2.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Coombes</surname>
                      <given-names>RC</given-names>
                    </name>
                    <name>
                      <surname>Dady</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Parsons</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>McCready</surname>
                      <given-names>VR</given-names>
                    </name>
                    <name>
                      <surname>Ford</surname>
                      <given-names>HT</given-names>
                    </name>
                    <name>
                      <surname>Gazet</surname>
                      <given-names>JC</given-names>
                    </name>
                    <name>
                      <surname>Powles</surname>
                      <given-names>TJ</given-names>
                    </name>
                  </person-group>
                  <article-title>Assessment of response of bone metastases to systemic treatment in patients with breast cancer</article-title>
                  <source>Cancer</source>
                  <year>1983</year>
                  <volume>52</volume>
                  <fpage>610</fpage>
                  <lpage>614</lpage>
                  <pub-id pub-id-type="doi">10.1002/1097-0142(19830815)52:4&lt;610::AID-CNCR2820520406&gt;3.0.CO;2-5</pub-id>
                  <pub-id pub-id-type="pmid">6861098</pub-id>
                </element-citation>
              </ref>
              <ref id="CR3">
                <label>3.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Lecouvet</surname>
                      <given-names>FE</given-names>
                    </name>
                    <name>
                      <surname>Talbot</surname>
                      <given-names>JN</given-names>
                    </name>
                    <name>
                      <surname>Messiou</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Bourguet</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Liu</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>de Souza</surname>
                      <given-names>NM</given-names>
                    </name>
                    <collab>EORTC Imaging Group</collab>
                  </person-group>
                  <article-title>Monitoring the response of bone metastases to treatment with magnetic resonance imaging and nuclear medicine techniques: a review and position statement by the European Organisation for Research and Treatment of Cancer imaging group</article-title>
                  <source>Eur J Cancer</source>
                  <year>2014</year>
                  <volume>50</volume>
                  <fpage>2519</fpage>
                  <lpage>2531</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.ejca.2014.07.002</pub-id>
                  <pub-id pub-id-type="pmid">25139492</pub-id>
                </element-citation>
              </ref>
              <ref id="CR4">
                <label>4.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Larson</surname>
                      <given-names>SM</given-names>
                    </name>
                    <name>
                      <surname>Erdi</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Akhurst</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Mazumdar</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Macapinlac</surname>
                      <given-names>HA</given-names>
                    </name>
                    <name>
                      <surname>Finn</surname>
                      <given-names>RD</given-names>
                    </name>
                    <name>
                      <surname>Casilla</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Fazzari</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Srivastava</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Yeung</surname>
                      <given-names>HW</given-names>
                    </name>
                    <name>
                      <surname>Humm</surname>
                      <given-names>JL</given-names>
                    </name>
                    <name>
                      <surname>Guillem</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Downey</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Karpeh</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Cohen</surname>
                      <given-names>AE</given-names>
                    </name>
                    <name>
                      <surname>Ginsberg</surname>
                      <given-names>R</given-names>
                    </name>
                  </person-group>
                  <article-title>Tumor treatment response based on visual and quantitative changes in global tumor glycolysis using PET-FDG imaging. The visual response score and the change in total lesion glycolysis</article-title>
                  <source>Clin Positron Imaging</source>
                  <year>1999</year>
                  <volume>2</volume>
                  <fpage>159</fpage>
                  <lpage>171</lpage>
                  <pub-id pub-id-type="doi">10.1016/S1095-0397(99)00016-3</pub-id>
                  <pub-id pub-id-type="pmid">14516540</pub-id>
                </element-citation>
              </ref>
              <ref id="CR5">
                <label>5.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Zhu</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Ma</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Niu</surname>
                      <given-names>Z</given-names>
                    </name>
                    <name>
                      <surname>Zheng</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Han</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Zhao</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Yu</surname>
                      <given-names>J</given-names>
                    </name>
                  </person-group>
                  <article-title>Prognostic significance of metabolic parameters measured by <sup>18</sup>F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with small cell lung cancer</article-title>
                  <source>Lung Cancer</source>
                  <year>2011</year>
                  <volume>73</volume>
                  <fpage>332</fpage>
                  <lpage>337</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.lungcan.2011.01.007</pub-id>
                  <pub-id pub-id-type="pmid">21292341</pub-id>
                </element-citation>
              </ref>
              <ref id="CR6">
                <label>6.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>De Giorgi</surname>
                      <given-names>U</given-names>
                    </name>
                    <name>
                      <surname>Mego</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Rohren</surname>
                      <given-names>EM</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title><sup>18</sup>F-FDG PET/CT findings and circulating tumor cell counts in the monitoring of systemic therapies for bone metastases from breast cancer</article-title>
                  <source>J Nucl Med</source>
                  <year>2010</year>
                  <volume>51</volume>
                  <fpage>1213</fpage>
                  <lpage>1218</lpage>
                  <pub-id pub-id-type="doi">10.2967/jnumed.110.076455</pub-id>
                  <pub-id pub-id-type="pmid">20660382</pub-id>
                </element-citation>
              </ref>
              <ref id="CR7">
                <label>7.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Specht</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Tam</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Kurland</surname>
                      <given-names>B</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Serial 2-[<sup>18</sup>F] fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP)</article-title>
                  <source>Breast Cancer Res Treat</source>
                  <year>2007</year>
                  <volume>105</volume>
                  <fpage>87</fpage>
                  <lpage>94</lpage>
                  <pub-id pub-id-type="doi">10.1007/s10549-006-9435-1</pub-id>
                  <pub-id pub-id-type="pmid">17268819</pub-id>
                </element-citation>
              </ref>
              <ref id="CR8">
                <label>8.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Stafford</surname>
                      <given-names>SE</given-names>
                    </name>
                    <name>
                      <surname>Gralow</surname>
                      <given-names>JR</given-names>
                    </name>
                    <name>
                      <surname>Schubert</surname>
                      <given-names>EK</given-names>
                    </name>
                    <name>
                      <surname>Rinn</surname>
                      <given-names>KJ</given-names>
                    </name>
                    <name>
                      <surname>Dunnwald</surname>
                      <given-names>LK</given-names>
                    </name>
                    <name>
                      <surname>Livingston</surname>
                      <given-names>RB</given-names>
                    </name>
                    <name>
                      <surname>Mankoff</surname>
                      <given-names>DA</given-names>
                    </name>
                  </person-group>
                  <article-title>Use of serial FDG PET to measure the response of bone-dominant breast cancer to therapy</article-title>
                  <source>Acad Radiol</source>
                  <year>2002</year>
                  <volume>9</volume>
                  <fpage>913</fpage>
                  <lpage>921</lpage>
                  <pub-id pub-id-type="doi">10.1016/S1076-6332(03)80461-0</pub-id>
                  <pub-id pub-id-type="pmid">12186440</pub-id>
                </element-citation>
              </ref>
              <ref id="CR9">
                <label>9.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Doot</surname>
                      <given-names>RK</given-names>
                    </name>
                    <name>
                      <surname>Muzi</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Peterson</surname>
                      <given-names>LM</given-names>
                    </name>
                    <name>
                      <surname>Schubert</surname>
                      <given-names>EK</given-names>
                    </name>
                    <name>
                      <surname>Gralow</surname>
                      <given-names>JR</given-names>
                    </name>
                    <name>
                      <surname>Specht</surname>
                      <given-names>JM</given-names>
                    </name>
                    <name>
                      <surname>Mankoff</surname>
                      <given-names>DA</given-names>
                    </name>
                  </person-group>
                  <article-title>Kinetic analysis of <sup>18</sup>F-fluoride PET images of breast cancer bone metastases</article-title>
                  <source>J Nucl Med</source>
                  <year>2010</year>
                  <volume>51</volume>
                  <fpage>521</fpage>
                  <lpage>527</lpage>
                  <pub-id pub-id-type="doi">10.2967/jnumed.109.070052</pub-id>
                  <pub-id pub-id-type="pmid">20237040</pub-id>
                </element-citation>
              </ref>
              <ref id="CR10">
                <label>10.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Orlhac</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Soussan</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Maisonobe</surname>
                      <given-names>JA</given-names>
                    </name>
                    <name>
                      <surname>Garcia</surname>
                      <given-names>CA</given-names>
                    </name>
                    <name>
                      <surname>Vanderlinden</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Buvat</surname>
                      <given-names>I</given-names>
                    </name>
                  </person-group>
                  <article-title>Tumor texture analysis in 18F-FDG PET: relationships between texture parameters, histogram indices, standardized uptake values, metabolic volumes, and total lesion glycolysis</article-title>
                  <source>J Nucl Med</source>
                  <year>2014</year>
                  <volume>55</volume>
                  <fpage>414</fpage>
                  <lpage>422</lpage>
                  <pub-id pub-id-type="doi">10.2967/jnumed.113.129858</pub-id>
                  <pub-id pub-id-type="pmid">24549286</pub-id>
                </element-citation>
              </ref>
              <ref id="CR11">
                <label>11.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Vaidya</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Creach</surname>
                      <given-names>KM</given-names>
                    </name>
                    <name>
                      <surname>Frye</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Dehdashti</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Bradley</surname>
                      <given-names>JD</given-names>
                    </name>
                    <name>
                      <surname>el Naqa</surname>
                      <given-names>I</given-names>
                    </name>
                  </person-group>
                  <article-title>Combined PET/CT image characteristics for radiotherapy tumor response in lung cancer</article-title>
                  <source>Radiother Oncol</source>
                  <year>2012</year>
                  <volume>102</volume>
                  <fpage>239</fpage>
                  <lpage>245</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.radonc.2011.10.014</pub-id>
                  <pub-id pub-id-type="pmid">22098794</pub-id>
                </element-citation>
              </ref>
              <ref id="CR12">
                <label>12.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Cook</surname>
                      <given-names>GJ</given-names>
                    </name>
                    <name>
                      <surname>Yip</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Siddique</surname>
                      <given-names>M</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Are pretreatment <sup>18</sup>F-FDG PET tumor textural features in non-small cell lung cancer associated with response and survival after chemoradiotherapy?</article-title>
                  <source>J Nucl Med</source>
                  <year>2013</year>
                  <volume>54</volume>
                  <fpage>19</fpage>
                  <lpage>26</lpage>
                  <pub-id pub-id-type="doi">10.2967/jnumed.112.107375</pub-id>
                  <pub-id pub-id-type="pmid">23204495</pub-id>
                </element-citation>
              </ref>
              <ref id="CR13">
                <label>13.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>El Naqa</surname>
                      <given-names>I</given-names>
                    </name>
                    <name>
                      <surname>Grigsby</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Apte</surname>
                      <given-names>A</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Exploring feature-based approaches in PET images for predicting cancer treatment outcomes</article-title>
                  <source>Pattern Recogn</source>
                  <year>2009</year>
                  <volume>42</volume>
                  <fpage>1162</fpage>
                  <lpage>1171</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.patcog.2008.08.011</pub-id>
                </element-citation>
              </ref>
              <ref id="CR14">
                <label>14.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Yang</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Thomas</surname>
                      <given-names>MA</given-names>
                    </name>
                    <name>
                      <surname>Dehdashti</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Grigsby</surname>
                      <given-names>PW</given-names>
                    </name>
                  </person-group>
                  <article-title>Temporal analysis of intratumoral metabolic heterogeneity characterized by textural features in cervical cancer</article-title>
                  <source>Eur J Nucl Med Mol Imaging</source>
                  <year>2013</year>
                  <volume>40</volume>
                  <fpage>716</fpage>
                  <lpage>727</lpage>
                  <pub-id pub-id-type="doi">10.1007/s00259-012-2332-4</pub-id>
                  <pub-id pub-id-type="pmid">23340594</pub-id>
                </element-citation>
              </ref>
              <ref id="CR15">
                <label>15.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Tixier</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Le Rest</surname>
                      <given-names>CC</given-names>
                    </name>
                    <name>
                      <surname>Hatt</surname>
                      <given-names>M</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Intratumor heterogeneity characterized by textural features on baseline <sup>18</sup>F-FDG PET images predicts response to concomitant radiochemotherapy in esophageal cancer</article-title>
                  <source>J Nucl Med</source>
                  <year>2011</year>
                  <volume>52</volume>
                  <fpage>369</fpage>
                  <lpage>378</lpage>
                  <pub-id pub-id-type="doi">10.2967/jnumed.110.082404</pub-id>
                  <pub-id pub-id-type="pmid">21321270</pub-id>
                </element-citation>
              </ref>
              <ref id="CR16">
                <label>16.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Tan</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Kligerman</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Chen</surname>
                      <given-names>W</given-names>
                    </name>
                    <name>
                      <surname>Lu</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Kim</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Feigenberg</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>D'Souza</surname>
                      <given-names>WD</given-names>
                    </name>
                    <name>
                      <surname>Suntharalingam</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Lu</surname>
                      <given-names>W</given-names>
                    </name>
                  </person-group>
                  <article-title>Spatial-temporal [(1)(8)F]FDG-PET features for predicting pathologic response of esophageal cancer to neoadjuvant chemoradiation therapy</article-title>
                  <source>Int J Radiat Oncol Biol Phys</source>
                  <year>2013</year>
                  <volume>85</volume>
                  <fpage>1375</fpage>
                  <lpage>1382</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.ijrobp.2012.10.017</pub-id>
                  <pub-id pub-id-type="pmid">23219566</pub-id>
                </element-citation>
              </ref>
              <ref id="CR17">
                <label>17.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Dong</surname>
                      <given-names>X</given-names>
                    </name>
                    <name>
                      <surname>Xing</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Wu</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Fu</surname>
                      <given-names>Z</given-names>
                    </name>
                    <name>
                      <surname>Wan</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Li</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Yin</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Sun</surname>
                      <given-names>X</given-names>
                    </name>
                    <name>
                      <surname>Yu</surname>
                      <given-names>J</given-names>
                    </name>
                  </person-group>
                  <article-title>Three-dimensional positron emission tomography image texture analysis of esophageal squamous cell carcinoma: relationship between tumor <sup>18</sup>F-fluorodeoxyglucose uptake heterogeneity, maximum standardized uptake value, and tumor stage</article-title>
                  <source>Nucl Med Commun</source>
                  <year>2013</year>
                  <volume>34</volume>
                  <fpage>40</fpage>
                  <lpage>46</lpage>
                  <pub-id pub-id-type="doi">10.1097/MNM.0b013e32835ae50c</pub-id>
                  <pub-id pub-id-type="pmid">23111378</pub-id>
                </element-citation>
              </ref>
              <ref id="CR18">
                <label>18.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Eary</surname>
                      <given-names>JF</given-names>
                    </name>
                    <name>
                      <surname>O’Sullivan</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>O’Sullivan</surname>
                      <given-names>J</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Spatial heterogeneity in sarcoma <sup>18</sup>F-FDG uptake as a predictor of patient outcome</article-title>
                  <source>J Nucl Med</source>
                  <year>2008</year>
                  <volume>49</volume>
                  <fpage>1973</fpage>
                  <lpage>1979</lpage>
                  <pub-id pub-id-type="doi">10.2967/jnumed.108.053397</pub-id>
                  <pub-id pub-id-type="pmid">18997052</pub-id>
                </element-citation>
              </ref>
              <ref id="CR19">
                <label>19.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Yu</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Caldwell</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Mah</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Poon</surname>
                      <given-names>I</given-names>
                    </name>
                    <name>
                      <surname>Balogh</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>MacKenzie</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Khaouam</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Tirona</surname>
                      <given-names>R</given-names>
                    </name>
                  </person-group>
                  <article-title>Automated radiation targeting in head-and-neck cancer using region-based texture analysis of PET and CT images</article-title>
                  <source>Int J Radiat Oncol Biol Phys</source>
                  <year>2009</year>
                  <volume>75</volume>
                  <fpage>618</fpage>
                  <lpage>625</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.ijrobp.2009.04.043</pub-id>
                  <pub-id pub-id-type="pmid">19683403</pub-id>
                </element-citation>
              </ref>
              <ref id="CR20">
                <label>20.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Goh</surname>
                      <given-names>V</given-names>
                    </name>
                    <name>
                      <surname>Ganeshan</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Nathan</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Juttla</surname>
                      <given-names>JK</given-names>
                    </name>
                    <name>
                      <surname>Vinayan</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Miles</surname>
                      <given-names>KA</given-names>
                    </name>
                  </person-group>
                  <article-title>Assessment of response to tyrosine kinase inhibitors in metastatic renal cell cancer: CT texture as a predictive biomarker</article-title>
                  <source>Radiology</source>
                  <year>2011</year>
                  <volume>261</volume>
                  <fpage>165</fpage>
                  <lpage>171</lpage>
                  <pub-id pub-id-type="doi">10.1148/radiol.11110264</pub-id>
                  <pub-id pub-id-type="pmid">21813743</pub-id>
                </element-citation>
              </ref>
              <ref id="CR21">
                <label>21.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Cook</surname>
                      <given-names>GJR</given-names>
                    </name>
                    <name>
                      <surname>O’Brien</surname>
                      <given-names>ME</given-names>
                    </name>
                    <name>
                      <surname>Siddique</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Chicklore</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Loi</surname>
                      <given-names>HY</given-names>
                    </name>
                    <name>
                      <surname>Sharma</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Punwani</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Bassett</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Goh</surname>
                      <given-names>V</given-names>
                    </name>
                    <name>
                      <surname>Chua</surname>
                      <given-names>S</given-names>
                    </name>
                  </person-group>
                  <article-title>Non small cell lung cancer treated with erlotinib: heterogeneity of <sup>18</sup>F-FDG uptake at PET-association with treatment response and prognosis</article-title>
                  <source>Radiology</source>
                  <year>2015</year>
                  <volume>276</volume>
                  <fpage>883</fpage>
                  <lpage>893</lpage>
                  <pub-id pub-id-type="doi">10.1148/radiol.2015141309</pub-id>
                  <pub-id pub-id-type="pmid">25897473</pub-id>
                </element-citation>
              </ref>
              <ref id="CR22">
                <label>22.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Haralick</surname>
                      <given-names>RM</given-names>
                    </name>
                    <name>
                      <surname>Shanmugan Dinstein</surname>
                      <given-names>KI</given-names>
                    </name>
                  </person-group>
                  <article-title>Textural features for image classification</article-title>
                  <source>IEEE Trans Syst Man Cybern</source>
                  <year>1973</year>
                  <volume>3</volume>
                  <fpage>610</fpage>
                  <lpage>621</lpage>
                  <pub-id pub-id-type="doi">10.1109/TSMC.1973.4309314</pub-id>
                </element-citation>
              </ref>
              <ref id="CR23">
                <label>23.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Rohren</surname>
                      <given-names>EM</given-names>
                    </name>
                    <name>
                      <surname>Etchebehere</surname>
                      <given-names>EC</given-names>
                    </name>
                    <name>
                      <surname>Araujo</surname>
                      <given-names>JC</given-names>
                    </name>
                    <name>
                      <surname>Hobbs</surname>
                      <given-names>BP</given-names>
                    </name>
                    <name>
                      <surname>Swanston</surname>
                      <given-names>NM</given-names>
                    </name>
                    <name>
                      <surname>Everding</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Moody</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Macapinlac</surname>
                      <given-names>HA</given-names>
                    </name>
                  </person-group>
                  <article-title>Determination of skeletal tumor burden on <sup>18</sup>F-fluoride PET/CT</article-title>
                  <source>J Nucl Med</source>
                  <year>2015</year>
                  <volume>56</volume>
                  <fpage>1507</fpage>
                  <lpage>1512</lpage>
                  <pub-id pub-id-type="doi">10.2967/jnumed.115.156026</pub-id>
                  <pub-id pub-id-type="pmid">26135112</pub-id>
                </element-citation>
              </ref>
              <ref id="CR24">
                <label>24.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Hatt</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Majdoub</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Vallieres</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Tixier</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>le Rest</surname>
                      <given-names>CC</given-names>
                    </name>
                    <name>
                      <surname>Groheux</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Hindie</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Martineau</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Pradier</surname>
                      <given-names>O</given-names>
                    </name>
                    <name>
                      <surname>Hustinx</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Perdrisot</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Guillevin</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>el Naqa</surname>
                      <given-names>I</given-names>
                    </name>
                    <name>
                      <surname>Visvikis</surname>
                      <given-names>D</given-names>
                    </name>
                  </person-group>
                  <article-title><sup>18</sup>F-FDG PET uptake characterization through texture analysis: investigating the complementary nature of heterogeneity and functional tumor volume in a multi-cancer site patient cohort</article-title>
                  <source>J Nucl Med</source>
                  <year>2015</year>
                  <volume>56</volume>
                  <fpage>38</fpage>
                  <lpage>44</lpage>
                  <pub-id pub-id-type="doi">10.2967/jnumed.114.144055</pub-id>
                  <pub-id pub-id-type="pmid">25500829</pub-id>
                </element-citation>
              </ref>
              <ref id="CR25">
                <label>25.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Brooks</surname>
                      <given-names>FJ</given-names>
                    </name>
                    <name>
                      <surname>Grigsby</surname>
                      <given-names>PW</given-names>
                    </name>
                  </person-group>
                  <article-title>The effect of small tumor volumes on studies of intratumoral heterogeneity of tracer uptake</article-title>
                  <source>J Nucl Med</source>
                  <year>2014</year>
                  <volume>55</volume>
                  <fpage>37</fpage>
                  <lpage>42</lpage>
                  <pub-id pub-id-type="doi">10.2967/jnumed.112.116715</pub-id>
                  <pub-id pub-id-type="pmid">24263086</pub-id>
                </element-citation>
              </ref>
              <ref id="CR26">
                <label>26.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Young</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Baum</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Cremerius</surname>
                      <given-names>U</given-names>
                    </name>
                    <name>
                      <surname>Herholz</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Hoekstra</surname>
                      <given-names>O</given-names>
                    </name>
                    <name>
                      <surname>Lammertsma</surname>
                      <given-names>AA</given-names>
                    </name>
                    <name>
                      <surname>Pruim</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Price</surname>
                      <given-names>P</given-names>
                    </name>
                  </person-group>
                  <article-title>Measurement of clinical and subclinical tumour response using [<sup>18</sup>F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group</article-title>
                  <source>Eur J Cancer</source>
                  <year>1999</year>
                  <volume>35</volume>
                  <fpage>1773</fpage>
                  <lpage>1782</lpage>
                  <pub-id pub-id-type="doi">10.1016/S0959-8049(99)00229-4</pub-id>
                  <pub-id pub-id-type="pmid">10673991</pub-id>
                </element-citation>
              </ref>
              <ref id="CR27">
                <label>27.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Cook</surname>
                      <given-names>GJR</given-names>
                    </name>
                    <name>
                      <surname>Parker</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Chua</surname>
                      <given-names>S</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title><sup>18</sup>F-fluoride PET: changes in uptake as a method to assess response in bone metastases from castrate-resistant prostate cancer patients treated with <sup>223</sup>Ra-chloride (Alpharadin)</article-title>
                  <source>EJMMI Res</source>
                  <year>2011</year>
                  <volume>1</volume>
                  <fpage>4</fpage>
                  <pub-id pub-id-type="doi">10.1186/2191-219X-1-4</pub-id>
                </element-citation>
              </ref>
              <ref id="CR28">
                <label>28.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Yu</surname>
                      <given-names>EY</given-names>
                    </name>
                    <name>
                      <surname>Duan</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Muzi</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Deng</surname>
                      <given-names>X</given-names>
                    </name>
                    <name>
                      <surname>Chin</surname>
                      <given-names>BB</given-names>
                    </name>
                    <name>
                      <surname>Alumkal</surname>
                      <given-names>JJ</given-names>
                    </name>
                    <name>
                      <surname>Taplin</surname>
                      <given-names>ME</given-names>
                    </name>
                    <name>
                      <surname>Taub</surname>
                      <given-names>JM</given-names>
                    </name>
                    <name>
                      <surname>Herman</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Higano</surname>
                      <given-names>CS</given-names>
                    </name>
                    <name>
                      <surname>Doot</surname>
                      <given-names>RK</given-names>
                    </name>
                    <name>
                      <surname>Hartfeil</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Febbo</surname>
                      <given-names>PG</given-names>
                    </name>
                    <name>
                      <surname>Mankoff</surname>
                      <given-names>DA</given-names>
                    </name>
                  </person-group>
                  <article-title>Castration-resistant prostate cancer bone metastasis response measured by <sup>18</sup>F-fluoride PET after treatment with dasatinib and correlation with progression-free survival: results from American College of Radiology Imaging Network 6687</article-title>
                  <source>J Nucl Med</source>
                  <year>2015</year>
                  <volume>56</volume>
                  <fpage>354</fpage>
                  <lpage>360</lpage>
                  <pub-id pub-id-type="doi">10.2967/jnumed.114.146936</pub-id>
                  <pub-id pub-id-type="pmid">25635138</pub-id>
                </element-citation>
              </ref>
              <ref id="CR29">
                <label>29.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Etchebehere</surname>
                      <given-names>EC</given-names>
                    </name>
                    <name>
                      <surname>Araujo</surname>
                      <given-names>JC</given-names>
                    </name>
                    <name>
                      <surname>Fox</surname>
                      <given-names>PS</given-names>
                    </name>
                    <name>
                      <surname>Swanston</surname>
                      <given-names>NM</given-names>
                    </name>
                    <name>
                      <surname>Macapinlac</surname>
                      <given-names>HA</given-names>
                    </name>
                    <name>
                      <surname>Rohren</surname>
                      <given-names>EM</given-names>
                    </name>
                  </person-group>
                  <article-title>Prognostic factors in patients treated with 223Ra: the role of skeletal tumor burden on baseline <sup>18</sup>F-fluoride PET/CT in predicting overall survival</article-title>
                  <source>J Nucl Med</source>
                  <year>2015</year>
                  <volume>56</volume>
                  <fpage>1177</fpage>
                  <lpage>1184</lpage>
                  <pub-id pub-id-type="doi">10.2967/jnumed.115.158626</pub-id>
                  <pub-id pub-id-type="pmid">26069307</pub-id>
                </element-citation>
              </ref>
              <ref id="CR30">
                <label>30.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Hyun</surname>
                      <given-names>SH</given-names>
                    </name>
                    <name>
                      <surname>Kim</surname>
                      <given-names>HS</given-names>
                    </name>
                    <name>
                      <surname>Choi</surname>
                      <given-names>SH</given-names>
                    </name>
                    <name>
                      <surname>Choi</surname>
                      <given-names>DW</given-names>
                    </name>
                    <name>
                      <surname>Lee</surname>
                      <given-names>JK</given-names>
                    </name>
                    <name>
                      <surname>Lee</surname>
                      <given-names>KH</given-names>
                    </name>
                    <name>
                      <surname>Park</surname>
                      <given-names>JO</given-names>
                    </name>
                    <name>
                      <surname>Lee</surname>
                      <given-names>KH</given-names>
                    </name>
                    <name>
                      <surname>Kim</surname>
                      <given-names>BT</given-names>
                    </name>
                    <name>
                      <surname>Choi</surname>
                      <given-names>JY</given-names>
                    </name>
                  </person-group>
                  <article-title>Intratumoral heterogeneity of <sup>18</sup>F-FDG uptake predicts survival in patients with pancreatic ductal adenocarcinoma</article-title>
                  <source>Eur J Nucl Med Mol Imaging</source>
                  <year>2016</year>
                  <volume>43</volume>
                  <fpage>1461</fpage>
                  <lpage>1468</lpage>
                  <pub-id pub-id-type="doi">10.1007/s00259-016-3316-6</pub-id>
                  <pub-id pub-id-type="pmid">26872788</pub-id>
                </element-citation>
              </ref>
              <ref id="CR31">
                <label>31.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Huyge</surname>
                      <given-names>V</given-names>
                    </name>
                    <name>
                      <surname>Garcia</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Alexiou</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Ameye</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Vanderlinden</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Lemort</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Bergmann</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Awada</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Body</surname>
                      <given-names>JJ</given-names>
                    </name>
                    <name>
                      <surname>Flamen</surname>
                      <given-names>P</given-names>
                    </name>
                  </person-group>
                  <article-title>Heterogeneity of metabolic response to systemic therapy in metastatic breast cancer patients</article-title>
                  <source>Clin Oncol</source>
                  <year>2010</year>
                  <volume>22</volume>
                  <fpage>818</fpage>
                  <lpage>827</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.clon.2010.05.021</pub-id>
                </element-citation>
              </ref>
              <ref id="CR32">
                <label>32.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Wade</surname>
                      <given-names>AA</given-names>
                    </name>
                    <name>
                      <surname>Scott</surname>
                      <given-names>JA</given-names>
                    </name>
                    <name>
                      <surname>Kuter</surname>
                      <given-names>I</given-names>
                    </name>
                    <name>
                      <surname>Fischman</surname>
                      <given-names>AJ</given-names>
                    </name>
                  </person-group>
                  <article-title>Flare response in <sup>18</sup>F-fluoride ion PET bone scanning</article-title>
                  <source>Am J Roentgenol</source>
                  <year>2006</year>
                  <volume>186</volume>
                  <fpage>1783</fpage>
                  <lpage>1786</lpage>
                  <pub-id pub-id-type="doi">10.2214/AJR.05.0225</pub-id>
                  <pub-id pub-id-type="pmid">16714674</pub-id>
                </element-citation>
              </ref>
              <ref id="CR33">
                <label>33.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Cook</surname>
                      <given-names>GJ</given-names>
                    </name>
                    <name>
                      <surname>Taylor</surname>
                      <given-names>BP</given-names>
                    </name>
                    <name>
                      <surname>Glendenning</surname>
                      <given-names>J</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Heterogeneity of treatment response in skeletal metastases from breast cancer in <sup>18</sup>F-fluoride and 18F-FDG PET</article-title>
                  <source>Nucl Med Commun</source>
                  <year>2015</year>
                  <volume>36</volume>
                  <fpage>515</fpage>
                  <lpage>516</lpage>
                  <pub-id pub-id-type="doi">10.1097/MNM.0000000000000303</pub-id>
                </element-citation>
              </ref>
              <ref id="CR34">
                <label>34.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Cook</surname>
                      <given-names>GJ</given-names>
                    </name>
                    <name>
                      <surname>Azad</surname>
                      <given-names>GK</given-names>
                    </name>
                    <name>
                      <surname>Goh</surname>
                      <given-names>V</given-names>
                    </name>
                  </person-group>
                  <article-title>Imaging bone metastases in breast cancer: staging and response assessment</article-title>
                  <source>J Nucl Med</source>
                  <year>2016</year>
                  <volume>57</volume>
                  <issue>Suppl 1</issue>
                  <fpage>27s</fpage>
                  <lpage>33s</lpage>
                  <pub-id pub-id-type="doi">10.2967/jnumed.115.157867</pub-id>
                  <pub-id pub-id-type="pmid">26834098</pub-id>
                </element-citation>
              </ref>
              <ref id="CR35">
                <label>35.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>JH</surname>
                      <given-names>O</given-names>
                    </name>
                    <name>
                      <surname>Lodge</surname>
                      <given-names>MA</given-names>
                    </name>
                    <name>
                      <surname>Wahl</surname>
                      <given-names>RL</given-names>
                    </name>
                  </person-group>
                  <article-title>Practical PERCIST: a simplified guide to PET respons e criteria in solid tumors 1.0</article-title>
                  <source>Radiology</source>
                  <year>2016</year>
                  <volume>280</volume>
                  <fpage>576</fpage>
                  <lpage>584</lpage>
                  <pub-id pub-id-type="doi">10.1148/radiol.2016142043</pub-id>
                  <pub-id pub-id-type="pmid">26909647</pub-id>
                </element-citation>
              </ref>
              <ref id="CR36">
                <label>36.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Desseroit</surname>
                      <given-names>MC</given-names>
                    </name>
                    <name>
                      <surname>Tixier</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Weber</surname>
                      <given-names>WA</given-names>
                    </name>
                    <name>
                      <surname>Siegel</surname>
                      <given-names>BA</given-names>
                    </name>
                    <name>
                      <surname>Cheze le Rest</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Visvikis</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Hatt</surname>
                      <given-names>M</given-names>
                    </name>
                  </person-group>
                  <article-title>Reliability of PET/CT shape and heterogeneity features in functional and morphologic components of non-small cell lung cancer tumors: a repeatability analysis in a prospective multicenter cohort</article-title>
                  <source>J Nucl Med</source>
                  <year>2017</year>
                  <volume>58</volume>
                  <fpage>406</fpage>
                  <lpage>411</lpage>
                  <pub-id pub-id-type="doi">10.2967/jnumed.116.180919</pub-id>
                  <pub-id pub-id-type="pmid">27765856</pub-id>
                </element-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
